ABEONA THERAPEUTICS INC. ABEO
Therapeutics Inc., a Delaware corporation (together with our subsidiaries, "we," "our," "Abeona"
or the "Company"), is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening
diseases. On April 28, 2025, the U.S. Food and Drug Administration ("FDA") approved ZEVASKYN® (prademagene
zamikeracel) gene-modified cellular sheets, also known as ZEVASKYN®, as the first and only autologous cell-based gene
Last close
6.00
2026-09-04
Market cap
$343.1M
2026-06-30 share count
52-week range
4.00 - 7.65
Valuation FY2025 figures against the last close
P/S59.0x
P/E5.9x
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS1.01
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.8M | — | $3.5M | $1.4M | $3.0M | $10.0M | — | $3.0M | $837.0K | $889.0K |
| Cost of revenue | $1.5M | — | — | — | — | — | — | — | — | — |
| Gross profit | $4.3M | — | — | — | — | — | — | — | — | — |
| R&D | $26.8M | $34.4M | $31.1M | $29.0M | $38.7M | $30.1M | $48.6M | $38.7M | $17.0M | $10.7M |
| SG&A | $65.0M | $29.9M | $19.0M | $17.3M | $21.6M | $23.8M | $20.7M | $20.1M | $10.9M | $13.3M |
| Total operating expenses | $95.3M | $64.2M | $50.6M | $52.3M | $92.8M | $91.4M | $77.1M | $61.2M | $28.7M | $24.8M |
| Operating income | -$89.4M | -$64.2M | -$47.1M | -$50.9M | -$89.8M | -$81.4M | -$77.1M | -$58.2M | -$27.8M | -$23.9M |
| Interest expense | $3.7M | $4.2M | $418.0K | $736.0K | $3.7M | $4.1M | — | — | — | — |
| Pre-tax income | $71.3M | -$63.7M | — | — | — | — | — | -$56.7M | -$27.3M | -$21.9M |
| Income tax | $100.0K | — | — | — | — | — | — | $0 | $0 | $0 |
| Net income | -$71.2M | $63.7M | $54.2M | -$39.7M | -$84.9M | -$84.2M | -$76.3M | -$56.7M | -$27.3M | -$21.9M |
| EPS, basic | 1.34 | -1.55 | -2.53 | -5.53 | -21.57 | — | — | — | — | — |
| EPS, diluted | 1.01 | -1.55 | -2.53 | -5.53 | -0.86 | -0.91 | -1.51 | -1.19 | -0.66 | -0.64 |
| Shares, diluted (wtd. avg.) | $66.1M | $41.0M | $21.4M | $7.9M | $3.9M | — | — | — | — | $34.2M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $78.4M | $23.4M | $14.5M | $14.2M | $32.9M | $12.6M | $129.3M | $18.8M | $137.8M | $69.1M |
| Short-term investments | $113.0M | $74.4M | $37.8M | $37.9M | $12.1M | $82.4M | — | $66.2M | $0 | — |
| Receivables | $6.1M | — | — | — | $3.0M | — | — | $81.0K | $107.0K | $124.0K |
| Inventory | $5.5M | — | — | — | — | — | — | — | — | — |
| Total current assets | $204.9M | $100.9M | $55.7M | $53.1M | $56.3M | $97.7M | $132.4M | $88.9M | $140.6M | $69.4M |
| Property, plant and equipment | $9.9M | $4.4M | $3.5M | $5.7M | $12.3M | $11.3M | $13.2M | $9.4M | $1.4M | $721.0K |
| Goodwill | — | — | — | — | — | $32.5M | $32.5M | $32.5M | $32.5M | $32.5M |
| Other intangibles | — | — | — | — | $1.4M | $1.5M | $36.2M | $43.0M | $4.0M | $8.4M |
| Total assets | $219.6M | $108.9M | $64.0M | $64.2M | $79.6M | $151.2M | $223.4M | $174.4M | $178.8M | $111.1M |
| Accounts payable | $7.9M | $3.4M | $1.9M | $1.8M | $4.3M | $4.7M | $3.8M | $6.1M | $1.9M | $3.7M |
| Short-term debt | $12.2M | $5.9M | — | — | — | — | — | — | — | — |
| Total current liabilities | $29.6M | $16.6M | $13.4M | $7.8M | $16.6M | $42.0M | $38.7M | $20.4M | $5.6M | $8.3M |
| Long-term debt | $7.8M | $13.0M | — | — | — | — | — | — | — | — |
| Total liabilities | $60.4M | $64.9M | $49.2M | $37.5M | $37.2M | $48.6M | $45.0M | $40.4M | $8.7M | $12.0M |
| Retained earnings | -$742.1M | -$813.3M | -$749.5M | -$695.3M | -$655.6M | -$570.7M | -$486.5M | -$410.2M | $2.6M | -$332.5M |
| Total equity | $159.2M | $44.0M | $14.8M | $26.8M | $42.4M | $102.6M | $178.4M | $134.0M | $170.1M | $99.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$76.3M | -$56.0M | -$37.0M | -$43.5M | -$65.7M | -$35.0M | -$62.8M | -$39.1M | -$22.7M | -$13.0M |
| Depreciation and amortisation | $2.5M | $2.0M | $2.3M | $3.1M | $3.2M | $4.6M | $7.8M | $2.4M | $741.0K | $825.0K |
| Stock-based compensation | $10.8M | $6.6M | $4.8M | $3.1M | — | — | — | — | — | — |
| Capital expenditure | $8.0M | $2.4M | $331.0K | $130.0K | $4.2M | $1.3M | $6.3M | $9.2M | $860.0K | $519.0K |
| Investing cash flow | $105.0M | -$39.2M | $208.0K | -$24.0M | $66.1M | -$83.7M | $60.0M | -$85.1M | -$860.0K | -$519.0K |
| Financing cash flow | $26.0M | $104.1M | $37.1M | $43.2M | $24.9M | $1.9M | $113.9M | $5.5M | $92.4M | $42.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-019153.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |